Oral care company Colgate-Palmolive stated on Thursday that toothpastes containing zinc or stannous and mouthwash formulas with cetylpyridinium chloride (CPC) neutralize the virus that causes COVID-19 by 99.9% based on laboratory programme Rutgers NJMS.
The studies are part of a Colgate research programme that includes clinical studies among infected people to assess the efficacy of oral care products in reducing the amount of the virus in the mouth, potentially slowing the transmission of the COVID-19 virus. The study was led by Dr David Alland, Chief of Infectious Diseases and director of the Center for COVID-19 Response and Pandemic Preparedness.
In the laboratory studies, which were conducted in partnership with Rutgers New Jersey Medical School's (NJMS) Public Health Research Institute and Regional Biosafety Laboratories, Colgate Total and Meridol toothpastes neutralized 99.9% of the virus after two minutes of contact. Colgate Plax and Colgate Total mouthwashes were similarly effective after 30 seconds. The results suggest that some toothpastes and mouthwashes may help reduce the spread of SARS-CoV-2 by temporarily reducing the amount of virus in the mouth.
In conjunction, the researchers plan to share their findings in December. Additional Colgate-supported clinical research studies on toothpaste and mouthwashes are in early stages at Rutgers, the Albert Einstein Institute in Sao Paulo, Brazil and at the University of North Carolina at Chapel Hill Adams School of Dentistry, with some 260 people with COVID-19 participating in these studies.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering